The combination of anti-PD-1 antibody and anti-CD40 agonistic antibody significantly reduced tumor growth compared to the IgG control, and to anti-PD-1 and anti-CD40 as monotherapies in subcutaneous, orthotopic and two plasmid-based murine iCCA models. The gene discussed is CD40; the disease is neoplasm.